Klydon (Pty) Ltd is a private company that has business operations in the gas- and solar energy markets; as well as in the medical imaging field and in the development and production of pharmaceuticals.

Klydon owns proprietary technology that is classified as dual-use technology and is registered in terms of the Nuclear Act of 1993 with the Council for Non-Proliferation of Weapons of Mass Destruction that operates in the Department of Trade and Industry. It is, furthermore, also registered with the International Atomic Energy Agency (IAEA) that is resident in Vienna.
In addition, the company, via the relevant subsidiary companies, has several licenses and registrations with the Medical Control Council (MCC) and the Pharmacy Council to be able to operate in the medical imaging field and for the production of pharmaceuticals under Good Manufacturing Practice (GMP) protocol.

Klydon's new technology enterprise has flourished in the new South Africa, benefitting from the nation's pool of intellectual capital and positive environment for technology innovation. Klydon's major achievement has been the development of a proprietary isotope enrichment technology called the Aerodynamic Separation Process or ASP.

Klydon's ASP technology offers a low cost solution for a myriad of applications in the energy, basic materials, semiconductor and medical sectors. As a leading edge developer of isotope separation technology for critical path applications, Klydon works with best-in-class industrial partners to commercialize and deploy the Klydon innovations on a global scale.